Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 - Balar, A V; Galsky, M D; Loriot, Y (J Clin Oncol, 2016)
(suppl abstr LBA4500)